Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Up 18.7% in March

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 34,300 shares, an increase of 18.7% from the March 15th total of 28,900 shares. Approximately 5.1% of the company’s shares are sold short. Based on an average trading volume of 122,800 shares, the short-interest ratio is presently 0.3 days.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Aptevo Therapeutics in a research report on Wednesday, April 10th. They set a “hold” rating on the stock.

Hedge Funds Weigh In On Aptevo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP bought a new position in shares of Aptevo Therapeutics during the 4th quarter worth about $29,000. Virtu Financial LLC bought a new position in Aptevo Therapeutics in the 2nd quarter valued at about $46,000. Citadel Advisors LLC bought a new position in Aptevo Therapeutics in the 4th quarter valued at about $47,000. Renaissance Technologies LLC lifted its position in Aptevo Therapeutics by 45.8% in the 2nd quarter. Renaissance Technologies LLC now owns 80,186 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 25,200 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Aptevo Therapeutics in the 1st quarter valued at about $152,000. Institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Price Performance

Shares of APVO stock traded down $0.06 on Monday, reaching $0.78. 465,918 shares of the company were exchanged, compared to its average volume of 204,535. The company has a 50-day moving average of $5.15 and a 200-day moving average of $8.05. Aptevo Therapeutics has a one year low of $0.76 and a one year high of $91.96.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.